Home / Going-concern warnings / Rani Therapeutics Holdings, Inc.
Filed 2026-03-26 路 Form 10-K 路 Accession 0001193125-26-126417 micro
Price before filing: $1.14 (2026-03-25 close, split/dividend-adjusted)
Market cap at flag: $194.4M (2026-03-26) 路 Latest: $119.9M (2026-10-16)
| Window | RANI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -21.9% | +8.9% | -30.8% | 2026-04-27 |
| 90 days | -32.7% | +11.9% | -44.6% | 2026-06-24 |
| 180 days | -31.8% | +18.3% | -50.1% | 2026-09-22 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.